Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia

In sickle cell disease (SCD), hydroxyurea (HU) treatment decreases the number of vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) by increasing fetal hemoglobin (HbF). Data are lacking regarding the frequency of HU dose modification or whether sub-therapeutic doses (

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2018-02, Vol.19 (3), p.681
Main Authors: Di Maggio, Rosario, Hsieh, Matthew M, Zhao, Xiongce, Calvaruso, Giuseppina, Rigano, Paolo, Renda, Disma, Tisdale, John F, Maggio, Aurelio
Format: Article
Language:English
Subjects:
Age
Blood
Diabetes
Females
fetal hemoglobin
Fetuses
Gender
Hemoglobin
Hydroxyurea
Kidney diseases
Medical records
Medical screening
Mortality
Patients
Phenotypes
sickle beta thalassemia
Sickle cell disease
Thalassemia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In sickle cell disease (SCD), hydroxyurea (HU) treatment decreases the number of vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) by increasing fetal hemoglobin (HbF). Data are lacking regarding the frequency of HU dose modification or whether sub-therapeutic doses (
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms19030681